C E Depuydt

Summary

Country: Belgium

Publications

  1. ncbi Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening
    C E Depuydt
    RIATOL, Department of Molecular Diagnostics, Sonic Healthcare Benelux, Antwerp, Belgium
    J Clin Microbiol 50:4073-7. 2012
  2. ncbi Changes in type-specific human papillomavirus load predict progression to cervical cancer
    Christophe E Depuydt
    RIATOL, Department of Molecular Diagnostics, Sonic Healthcare Benelux, Antwerp, Belgium
    J Cell Mol Med 16:3096-104. 2012
  3. ncbi Association of HIV infection with distribution and viral load of HPV types in Kenya: a survey with 820 female sex workers
    Stanley M F Luchters
    International Centre for Reproductive Health ICRH, Ghent University, Belgium
    BMC Infect Dis 10:18. 2010
  4. ncbi BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening
    Christophe E Depuydt
    Department of Molecular Pathology RIATOL, Sonic Healthcare, Emiel Vloorsstraat 9, B 2020, Antwerp, Belgium
    Cancer Epidemiol Biomarkers Prev 20:628-37. 2011
  5. ncbi Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and/or high-risk HPV detection?
    Christophe E Depuydt
    Laboratory for Clinical Pathology, Labo Lokeren, campus RIATOL, Amerikalei, Antwerp, Belgium
    J Cell Mol Med 13:4051-60. 2009
  6. ncbi Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women
    C E Depuydt
    Laboratory for Clinical Pathology Labo RIATOL, Antwerp, Belgium
    Br J Cancer 88:560-6. 2003
  7. ncbi Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi
    C E Depuydt
    Laboratory for Clinical Pathology Labo RIATOL, Antwerp, Belgium
    Cytopathology 17:374-81. 2006
  8. ncbi Cervical cytology biobanking: quality of DNA from archival cervical Pap-stained smears
    G A V Boulet
    Applied Molecular Biology Research AMBIOR, Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium
    J Clin Pathol 61:637-41. 2008
  9. ncbi Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types
    C E Depuydt
    Laboratory for Clinical Pathology Labo Lokeren, campus RIATOL, AML RIATOL group, Antwerp, Belgium
    J Cell Mol Med 11:881-91. 2007
  10. ncbi Correlation between laminin-5 immunohistochemistry and human papillomavirus status in squamous cervical carcinoma
    G A V Boulet
    Ambior IX, Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium
    J Clin Pathol 60:896-901. 2007

Collaborators

Detail Information

Publications13

  1. ncbi Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening
    C E Depuydt
    RIATOL, Department of Molecular Diagnostics, Sonic Healthcare Benelux, Antwerp, Belgium
    J Clin Microbiol 50:4073-7. 2012
    ..5 to 99.4%), with a kappa value of 0.96 (95% CI, 0.83 to 1.00). The qPCR assay used in this study can be considered a reliable HPV assay that fulfills the clinical validation criteria defined for use in cervical cancer screening...
  2. ncbi Changes in type-specific human papillomavirus load predict progression to cervical cancer
    Christophe E Depuydt
    RIATOL, Department of Molecular Diagnostics, Sonic Healthcare Benelux, Antwerp, Belgium
    J Cell Mol Med 16:3096-104. 2012
    ..0001). Serial type-specific viral load measurements predict the natural history of HPV infections and could be used to triage women in HPV-based cervical cancer screening...
  3. ncbi Association of HIV infection with distribution and viral load of HPV types in Kenya: a survey with 820 female sex workers
    Stanley M F Luchters
    International Centre for Reproductive Health ICRH, Ghent University, Belgium
    BMC Infect Dis 10:18. 2010
    ..Interactions between these infections pose substantial public health challenges, especially where HIV prevalence is high and HPV vaccine coverage low...
  4. ncbi BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening
    Christophe E Depuydt
    Department of Molecular Pathology RIATOL, Sonic Healthcare, Emiel Vloorsstraat 9, B 2020, Antwerp, Belgium
    Cancer Epidemiol Biomarkers Prev 20:628-37. 2011
    ....
  5. ncbi Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and/or high-risk HPV detection?
    Christophe E Depuydt
    Laboratory for Clinical Pathology, Labo Lokeren, campus RIATOL, Amerikalei, Antwerp, Belgium
    J Cell Mol Med 13:4051-60. 2009
    ....
  6. ncbi Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women
    C E Depuydt
    Laboratory for Clinical Pathology Labo RIATOL, Antwerp, Belgium
    Br J Cancer 88:560-6. 2003
    ..7%). In Flanders, HSIL was most often associated with HPV types 16, 33, 35, 31, 18 and 51. Using thin-layer liquid-based cytology and PCR to detect HPV, it is feasible to screen large numbers of women...
  7. ncbi Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi
    C E Depuydt
    Laboratory for Clinical Pathology Labo RIATOL, Antwerp, Belgium
    Cytopathology 17:374-81. 2006
    ....
  8. ncbi Cervical cytology biobanking: quality of DNA from archival cervical Pap-stained smears
    G A V Boulet
    Applied Molecular Biology Research AMBIOR, Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium
    J Clin Pathol 61:637-41. 2008
    ..This study evaluates three commercial isolation methods and one digestion procedure for their ability to obtain DNA suitable for PCR from fixed and stained Pap smears...
  9. ncbi Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types
    C E Depuydt
    Laboratory for Clinical Pathology Labo Lokeren, campus RIATOL, AML RIATOL group, Antwerp, Belgium
    J Cell Mol Med 11:881-91. 2007
    ..3%) and specificity (MY09/11 PCR: 38.7%; type-specific PCRs: 76.14%), and predictive values for histologically confirmed CIN2+, suggest that type-specific PCRs could be used in a clinical setting as a reliable screening tool...
  10. ncbi Correlation between laminin-5 immunohistochemistry and human papillomavirus status in squamous cervical carcinoma
    G A V Boulet
    Ambior IX, Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium
    J Clin Pathol 60:896-901. 2007
    ..Integration of viral DNA into the host genome is a major contributing factor to malignant transformation. Viral load may influence integration...
  11. ncbi Cervical cytological screening and human papillomavirus DNA testing in Flanders
    S Sahebali
    Dienst Anatomo-pathologie, Universiteit Antwerpen, 2610 Wilrijk, Belgi
    Acta Clin Belg 58:211-9. 2003
    ..These results shed more light on HPV prevalence in Flanders and show that the MY09/MY11 consensus primer based detection system is very suitable for the detection of HPV infections in Flanders...
  12. ncbi Ki-67 immunocytochemistry in liquid based cervical cytology: useful as an adjunctive tool?
    S Sahebali
    Department of Pathology, University of Antwerp, B 2610 Antwerp, Belgium
    J Clin Pathol 56:681-6. 2003
    ..To test the ability of Ki-67 to detect cytological lesions in a screening setting and its use as a surrogate marker of human papillomavirus (HPV) infection...
  13. ncbi Age-restricted cervical screening
    C E Depuydt
    Int J Gynecol Cancer 13:564. 2003